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In this issue of Structure, Bista and colleagues report that inhibitors of the MDM2/p53 interaction can be
designed to interact with a transiently folded a-helical segment of the MDM2 lid region. This suggests that
targeting transient protein states in PPI inhibitor design could be a promising strategy to improve affinity
and/or selectivity profiles.Figure 1. Adaptability of the N-terminal Lid Region of MDM2
(A) Upon binding of p53, the N-terminal lid of MDM2 is displaced from the p53 binding site and remains
intrinsically disordered (Protein Data Bank [PDB] code 1YCR). Key hydrophobic residues of the p53
TAD1 domain are shown.
(B) Various states of theMDM2 apo (nmr) structure show that the lid (residues 21–24 are shown in green) is
predominantly in the closed state (PDB code 1Z1M).
(C) Binding of piperidinones to MDM2 leads to formation of an a-helical lid structure (residues 21–24) and
formation of a b strand (PDB code 4HBM). The NMR structure of the same complex shows that, in solution,
the b strand is only formed for residues 14–16 (Michelsen et al., 2012).
(D) YH300 induces a conformational rearrangement of Y100 and Y104 and interacts with the lid region of
MDM2 (PDB code 4MDQ). This creates a concave binding pocket on the MDM2 surface.Protein-protein interactions (PPI) are
essential for the regulation of diverse cell
functions. Their biological relevance in
many pathological processes makes
them attractive drug targets. Although
several effective small molecule inhibitors
of PPIs have been identified and are
currently in clinical trials, drug discovery
on PPI targets still presents a major chal-
lenge (Mullard, 2012). The flat, large, and
relatively featureless interaction surfaces
of PPIs are usually difficult to target with
small molecules. This typically results in
low hit rates for screening efforts against
PPI targets and indicates that the chemi-
cal space of existing compound libraries
could be biased toward targets with
classical binding pockets. Known PPI
inhibitors are usually larger, more three-
dimensional, and more rigid than typical
drug-like molecules (Mullard, 2012).
Therefore, novel strategies for the iden-
tification and rational design of small
molecule PPI inhibitors are required.
The p53-MDM2 PPI is a promising
target for the development of new anti-
cancer drugs. The tumor suppressor p53
plays a key role in DNA repair, cell cycle
arrest, and apoptosis (Brown et al.,
2009). MDM2 is one of the main negative
regulators of p53. It promotes ubiquitina-
tion and degradation of p53 and inhibits
its transcriptional activity. Structures of
the p53-MDM2 complex show that the
N-terminal domain of MDM2 interacts
mainly with the hydrophobic residues
Phe19, Trp23, and Leu26 of the p53
transactivation domain 1 (TAD1), which
forms a nascent helical structure (Fig-
ure 1A). MDM2 levels are upregulated
in many human cancers. Disrupting the
p53-MDM2 interaction is therefore apromising strategy to activate p53 and
induce cell cycle arrest or apoptosis in
cancer cells (Joerger and Fersht, 2008).
Several small molecule inhibitors have
been reported to inhibit the formation of
the p53-MDM2 complex, including theStructure 21, December 3, 2013nutlins, spirooxindole-containing com-
pounds, and 1,4-diazepinedione inhibi-
tors (Zhao et al., 2013). A common feature
of these compounds is that they mimic
hydrophobic interactions of p53 residues
Phe19, Trp23, and Leu26 with MDM2.ª2013 Elsevier Ltd All rights reserved 2095
Figure 2. Targeting Transient Protein States in PPI by Molecular Design or Fragment-Based Drug Discovery
(A and B) Binding sites of PPIs should, in principle, be flexible, allowing for more favored binding site conformations (A) and less preferred transient protein states
(TPS), where additional interactions are possible (B).
(C) The regular interaction partner (protein, green) should typically recognize a preferred binding site conformation.
(D) Major drug discovery efforts focus on mimicking the protein by a small molecule, peptidomimetic, or stapled peptide, generating molecules of higher
complexity to displace the protein and inhibit the interaction.
(E) Knowledge-driven molecular design, as applied by Bista et al. (2013) to prepare YH300, utilizes experimentally gained knowledge to target and stabilize such
a transient protein state. However, without such previously gained knowledge, design approaches are impractical. Sampling the conformational space of the
protein is certainly an exhausting task when starting from protein mimetics with higher molecular complexity.
(F–I) An alternative route to screen for binders and stabilizers of transient protein states can be fragment-based approaches.
(F and H) Several fragments (F1 and F3) will bind to different parts of the binding site not differentiating between a transient protein state and the common
binding site.
(G) Some of the fragments (F2) might be found to target and stabilize the transiently available part of the binding site (F2*).
(I) Linking, growing, or merging fragments (F3-F1-F2*), starting from such TPS-binders, could efficiently yield inhibitors of high structural complementarity to
classic protein mimetics.
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PreviewsRecently, Michelsen et al. (2012)
described a new piperidinone inhibitor
that binds to the p53 interaction site of
MDM2 and additionally induces partial
folding of the intrinsically disordered N
terminus of MDM2. Nuclear magnetic
resonance (NMR) and X-ray structures of
the MDM2-inhibitor complex show that
residues 14–16 form a short b strand
through ligand-mediated contacts and
the MDM2 lid residues 21–24 form a short
a helix (Figure 1B). In the MDM2 apo
structure, the lid region exists in a dy-
namic equilibrium between two states.
The more frequently populated ‘‘closed’’
state (Figure 1C) blocks the p53 binding
surface, whereas the ‘‘open’’ state re-
mains highly flexible (Showalter et al.,
2008). Targeting the flexible N terminus2096 Structure 21, December 3, 2013 ª2013could be a new strategy for small mole-
cule drug discovery on MDM2.
In this issue of Structure, Bista et al.
(2013) present the first p53-MDM2 inhibi-
tor that directly interacts with the tran-
siently folded a helix of the N-terminal lid
region. First, the authors identified the
compound KK271 using a pharmaco-
phore model of the key hydrophobic
interactions in the p53-MDM2 complex.
Surprisingly, the crystal structure of the
MDM2-KK271 complex revealed that
two KK271 molecules bind to MDM2.
One molecule fills the Phe19, Trp23, and
Leu26 subpockets, whereas the second
molecule occupies a new binding site
that is directly connected to the Leu26
subpocket. Conformational rearrange-
ment of Tyr100, Tyr104, and Leu54Elsevier Ltd All rights reservedenables the formation of this ‘‘expanded
Leu26 binding site,’’ which is mainly filled
by the benzyl moiety of KK271 (Bista
et al., 2013). Taking advantage of this
‘‘artifact,’’ design and synthesis of com-
pounds targeting the enlarged leucine
binding site yielded YH300, which is twice
as potent as KK271. Modifications of
KK271 include an additional 4-fluoro-
phenyl group that is linked by a short
oxymethylene linker to the core scaffold.
The crystal structure of the MDM2-
YH300 complex shows that the extended
Leu26 subpocket is occupied by the
4-fluorophenyl moiety. Intriguingly, the
N-terminal lid (residues 19–24) partially
covers the 4-fluorophenyl moiety, creat-
ing a concave binding pocket on the
MDM2 surface (Figure 1D). Stabilization
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is an exciting example of exploiting the
conformational adaptability of the lid and
could be a blueprint for novel types of
potent p53-MDM2 inhibitors.
MDMX is another important negative
regulator of p53 and a close structural
homolog of MDM2. The N-terminal bind-
ing sites of MDMX and MDM2 are highly
related and bind p53 in virtually identical
binding modes (Zhao et al., 2013).
Recently, the endogenous inhibitor litho-
cholic acid was found to bind to MDM2
and more preferentially to MDMX (Vogel
et al., 2012). Popowicz et al. (2010) pre-
viously described the inhibitor WK298,
which binds to the p53 binding site of
MDMX and a secondary site in close
proximity to the MDMX Leu26 subpocket.
This secondary MDMX binding site
resembles the expanded Leu26 pocket
in the KK271-MDM2 structure. However,
it is less concave than the corresponding
MDM2 site and might be more difficult
to target with rationally designed inhi-
bitors (Popowicz et al., 2010). So far,
there is no experimental evidence for a
potential transient interaction between
the N terminus and the N-terminal domain
of MDMX. The MDM2 lid residues 16–24
are not conserved in MDMX, and second-
ary structure prediction shows that the
corresponding region of MDMX has no
helix propensity. It is therefore unlikely
that the intrinsically disordered N termi-
nus of MDMX can be stabilized in a similar
way as observed in the YH300-MDM2
complex.
Targeting the flexibleMDM2N terminus
could be also useful for improving selec-tivity and toxicity profiles of inhibitors.
Recently, Brown et al. (2013) reported
that the cellular toxicity of small molecules
like the nutlins is mainly p53 independent.
Considering that the p53 TAD1 domain in-
teracts also with other proteins (e.g., p300
and TAFIIb), it is not surprising that small
molecules mimicking the p53 hotspot
residues show off-target toxicity. Addi-
tionally, the high lipophilicity of many
p53-MDM2 inhibitors may increase pro-
miscuous binding to proteins. Using an
extended pharmacophore model based
on the YH300-MDM2 complex could be
an interesting strategy for increasing
inhibitor specificity. Evaluation of YH300
in cellular assays should help to assess
its potential advantages over existing
MDM2 inhibitors.
How can this strategy of targeting tran-
sient protein states be extended to other
PPI targets? The typical flat PPI binding
interfaces without significant cavity depth
require ligands that are generally larger,
more three-dimensional, and more rigid
than usual drug molecules. These are
often inspired by nature, mimicking the
natural peptide or protein structure of
the PPI (Figures 2A–2D). In contrast to
regular binding pockets, the usually sol-
vent-exposed binding site residues might
be more flexible and can more easily
adapt to ligands. It is difficult to probe
such adaptable interfaces for transient
protein states, starting from large protein
mimetics of high molecular complexity
based on their usually sophisticated syn-
thetic accessibility (Figure 2E). Diversity-
oriented compound libraries of low
molecular complexity should be usefulStructure 21, December 3, 2013chemical probes for the detection of
structural plasticity and the identification
of such transient states (Figures 2F–2I).
This could be another forte of fragment-
based drug discovery, which has already
been quite successfully applied for PPI
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